TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.

Marie MullerFerdinando D'AmicoStefanos BonovasSilvio DaneseLaurent Peyrin-Biroulet

Published in: Journal of Crohn's & colitis (2021)

TNFi treatment is not associated with an increased risk of malignancy in IBD patients in real-life settings. Further large studies are needed to assess the prognosis of patients exposed to TNFi and risk of recurrence or new cancers in subjects with personal malignancy history.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes